Since securing a European patent for their proprietary cancer vaccine HER-Vaxx, Imugene (ASX: IMU) have been busy. The Company has…
Australian biotech company Immutep (ASX: IMM, NASDAQ: IMMP) has delivered impressive Phase I clinical trial results for its TACTI-mel trial…